Oncotarget
Dr. Blagosklonny’s Strategy: From Osimertinib to Preemptive Combinations
Jun 6, 2024
Dr. Blagosklonny, an expert in NSCLC treatment, discusses overcoming resistance in lung cancer therapy. He delves into the challenges with current EGFR inhibitors, the potential of Osimertinib as a third-generation TKI, and the use of preemptive combinations to enhance treatment outcomes.
08:07
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Osimertinib can be used preemptively to target resistant cells in NSCLC, extending progression-free survival.
- Preemptive combinations of Osimertinib, Afatinib, and Catmatinib aim to address multiple resistance mechanisms in NSCLC.
Deep dives
The Rise of Osemertinib as a Third-Generation EGFR TKI
Osemertinib was approved as a second-line therapy for NSCLC patients with the T790M mutation due to its ability to target this resistance mutation. This approval marked a shift in treatment strategy, as Osemertinib could be administered preemptively as a first-line treatment to prevent resistant cells from proliferating. Clinical trials showed Osemertinib significantly extended progression-free survival and response duration compared to first-generation inhibitors, highlighting its efficacy as a potent treatment option.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
